Mr Howling has over 25 years of healthcare industry experience in senior financial positions; including 11 years with Valeant Pharmaceuticals (formerly Biovail Corporation), as Chief Financial Officer, and Senior Vice President, Finance and Corporate Affairs; 5 years as Chief Financial Officer of Acerus Pharmaceuticals; and 5 years as Chief Financial Officer with Pharma Patch PLC.  During his career, Mr. Howling has contributed to the success of multiple start-up companies, taken companies through the IPO process and has collectively raised over US$2.3 billion in various forms of capital.

Most recently Mr. Howling contributed to Highland Therapeutics’ successful US$200 million debt financing led by Morgan Stanley, for the development of new medication to treat ADHD. Earlier in his career, Mr. Howling worked in senior financial management positions at Roberts Company Canada Limited, including roles of General Manager, Corporate Secretary and Controller, at Beecham Pharmaceuticals, and as an auditor with PricewaterhouseCoopers. Mr. Howling is a graduate of the ICD/Rotman Director Program and formerly a Certified Public Accountant (inactive license).

• 

  Chief Financial Officer in Translatum Medicus Inc.

  AMD is the leading cause of irreversible blindness in the world and is growing globally.